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stroke event incidence between groups was analyzed descrip-
tively and through a multivariate logistic regression analysis after
controlling for differences in baseline clinical and demographic
variables. RESULTS: Among 8176 study patients (3493 AM;
4683 IAM), AM patients were signiﬁcantly older [51.4  9.1
and 50.0  9.6 years, p < 0.01] and comprised of fewer males
(43.2% vs. 56.2%; p < 0.01). AM patients were more likely to be
at lower risk status at index date versus IAM patients (63% vs.
28%; p < 0.01), and had a signiﬁcantly lower Deyo-Charlson
comorbidity score (0.32  0.56 vs. 0.20  0.44; p < 0.01).
During follow-up, fewer AM patients experienced a stroke event
versus IAM patients (0.7% vs. 1.1%; p = 0.03) and thereby were
36% less likely to have a stroke event (OR: 0.64, 95% CI:
0.44–0.93; p < 0.01). CONCLUSION: Adhering to clinical
guideline treatment recommendations was likely to be associated
with subsequent stroke reductions and possible long-term cost
savings in this managed care population.
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OBJECTIVE: Injectable nicardipine is increasingly used in man-
aging neurovascular conditions. To understand its place in
therapy, we conducted an evidenced-based literature review.
METHODS: The English-language literature in OVID and
Cochrane databases was searched using combinations of these
terms: intracerebral hemorrhage (ICH), neurology, neurosurgery,
nicardipine, stroke, subarachnoid hemorrhage (SAH). Two-
hundred and twenty-three abstracts were identiﬁed; after inde-
pendent review by two individuals, four clinical guidelines, two
meta-analyses, and four randomized controlled trials (RCT) were
deemed relevant. RESULTS: In clinical guidelines, based on
expert opinion, nicardipine was recommended to manage
hypertension in 1) ischemic stroke patients eligible for acute
reperfusion therapy (alternatives: labetalol, nitropaste, and nitro-
prusside); and 2) ICH (alternatives: enalapril, esmolol, hydrala-
zine, labetalol, nitroprusside, nitroglycerin). In a meta-analysis,
nicardipine had no effect on death or dependency in patients with
aneurysmal SAH [RR:0.97 (95%CI:0.78–1.20)]; adverse events
were higher versus placebo [hypotension:34% vs. 5%; phlebi-
tis:22% vs. 5%; pulmonary edema + azotemia: 6% vs. 2%]. In
acute traumatic brain injury, nicardipine had no impact on death
and severe disability [RR:0.25 (95%CI:0.05–1.27)]. Nicar-
dipine’s effect on cerebral blood ﬂow was comparable to labe-
talol (+0.19  3.9 ml/100 g/min vs. -1.55  3.2 ml/100 g/min;
p = 0.39) in ICH, while it increased from baseline in SAH
patients (42.1  12.3 ml/100 g/min vs. 47  10.7 ml/100 g/min;
p < 0.05). In a craniotomy RCT, nicardipine was less effective
than labetalol in preventing emergent hypertension (50% vs.
82%; p = 0.05) and was associated with more tachycardia (20%
vs. 0%; p = 0.11), hypotension (15% vs. 0%; p = 0.23) and
higher cost ($23.65  6.62 vs. $5.23  2.0; p < 0.05). Mean
arterial pressure remained depressed 20 minutes post-infusion
compared to nitroprusside, despite lack of
cumulative nicardipine plasma levels [60  2 mmHg vs.
73  4 mmHg; p < 0.05] in spinal surgery patients. CONCLU-
SION: While nicardipine has a role in select neurovascular
indications, recommendations are based on expert opinion.
Moreover, a lack of beneﬁt has been demonstrated in meta-
analyses and RCT in other neurovascular indications, including
aneurysmal SAH and acute traumatic brain injury.
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OBJECTIVE: The current study evaluated the appropriate utili-
zation of ezetimibe add-on therapy to simvastatin and the cost-
consequences based upon the following outcomes: ezetimibe
response, LDL-C goal achievement, and switch to rosuvastatin.
METHODS: This was a retrospective review of VASDHS
medical records to identify patients with active prescriptions for
ezetimibe and simvastatin between January 1, 2004 and August
31, 2007. Base-case response was deﬁned as 10% LDL-C
reduction from baseline at study endpoint. Additional efﬁcacy
parameters included LDL-C goal achievement and switch to
rosuvastatin if LDL-C goal not met. Pre-post analyses for con-
tinuous and binomial data were performed using Wilcoxon-
ranked sum and McNemar’s tests, respectively. Cost analyses
were conducted from the payer perspective, utilizing total direct
costs. Average cost-effectiveness ratios (CER) were calculated
for (1) ezetimibe response, (2) LDL-C goal achievement, and
(3) switch to rosuvastatin. Sensitivity analyses were performed
varying the base-case response deﬁnition. RESULTS: Overall,
121 patients met inclusion. Baseline characteristics were as
follows: male 97.5%; Caucasian 78.5%; CHD 67.8%; diabetes
63.6%; symptomatic CAD 15.7%; PAD 18.2%; AAA 7.4%;
>20% 10-year risk-score 95.9%; LDL-C goal <100 mg/dL
95.9%; LDL-C goal <70 mg/dL 57.9%; and smoker 28.1%.
Pre-post comparisons showed signiﬁcant differences from base-
line LDL-C and cholesterol for both responders (p < 0.001,
p < 0.001) and non-responders (p = 0.028, p = 0.028). Overall,
88.4% of patients responded to ezetimibe, while 36% of non-
responders had their antilipemic regimen modiﬁed. In addition,
53% of patients reached LDL-C goal. Average CERs over a
9-month period using base-case response deﬁnition were:
$1705.64 per ezetimibe response, $2054.26 per LDL-C goal
achieved, and $2997.56 per switch to rosuvastatin. Sensitivity
analyses showed no change in trend for ezetimibe response, but
changes were observed for the latter parameters. CONCLU-
SION: There is beneﬁt in assessing both response rates as well as
LDL-C goal attainment when determining a cost-analysis of
ezetimibe add-on therapy to simvastatin.
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OBJECTIVE: Hyperlipidemia increases the risk for cardio-
vascular disease and control is pivotal for preventing subsequent
complications. Multidisciplinary interventions, including phar-
macists, are important for improving patients’ outcomes. Our
objective was to quantify the impact of pharmacist interventions
in enhancing patients’ clinical and humanistic outcomes.
METHODS: Two reviewers searched International Pharmaceu-
tical Abstracts, Medline, Embase, The Cochrane Central Register
of Controlled Trials, 3rd Quarter and CINAHL for pharmacist
interventions in hyperlipidemia. Quality was assessed using
Downs-Black scale. Data extracted included patients enrolled,
study characteristics, intervention type and pre- and post-
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